Latest News Archives

Xeltis raises an additional €20.5m of funding to advance aXess^™ toward FDA approval and US commercial launch

New investor Horizon 3 Healthcare led the round, which was supported by the European Innovation Council, Invest-NL, VI Partners, EQT…

Content Team In Clinical Publications, Latest News

Xeltis makes first commercial implant of aXess^™, its vascular access device for hemodialysis

Marks start of European commercial rollout of aXess™, bringing it into routine clinical practice Builds on CE mark approval in…

Content Team In Clinical Publications, Latest News

Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis

US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex hemodialysis patients representing real-world…

Content Team In Clinical Publications, Latest News

Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment

Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access 79% secondary…

Content Team In Finances, Latest News

Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization

CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data Xeltis advances ahead of schedule…

Content Team In Finances, Latest News

Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market

Up to €37.5m investment from the EIB, consisting of €10m upfront with optionality to further increase by an additional €27.5m…

Content Team In Clinical Trials, Latest News

Latest News

Xeltis raises an additional €20.5m of funding to advance aXess^™ toward FDA approval and US commercial launch

Xeltis makes first commercial implant of aXess^™, its vascular access device for hemodialysis

Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis

Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment

Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization

Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market

Xeltis poised for commercialization following excellent clinical data from aXess EU pivotal multicentre trial

Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in EU clinical trial

Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council

Xeltis expands Medical Advisory Board with World Leading Experts in Clinical Nephrology